The Journal for ImmunoTherapy of Cancer
is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.
Impact Factor: 10.9
Citescore: 16.8
All metrics >>
Highlighted Articles
Authors
The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.
The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.
Information is also provided on editorial policy, Open Access fees and formatting.
Liquid Biopsies
Letter:
Challenges in the implementation of ultrasensitive liquid biopsy approaches in precision oncology22 June 2023
Editorial:
Liquid biopsies coming of age: biology, emerging technologies, and clinical translation- An introduction to the JITC expert opinion special review series on liquid biopsies19 January 2023
Latest Articles
Immunotherapy biomarkers:
Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma1 December 2023
Immunotherapy biomarkers:
Hsa-LINC02418/mmu-4930573I07Rik regulated by METTL3 dictates anti-PD-L1 immunotherapeutic efficacy via enhancement of Trim21-mediated PD-L1 ubiquitination1 December 2023
Immunotherapy biomarkers:
Targeting integrin {alpha}5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition1 December 2023
Clinical/translational cancer immunotherapy:
Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma1 December 2023
Basic tumor immunology:
Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions1 December 2023
Most Read Articles
Clinical/translational cancer immunotherapy:
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, sing…21 January 2022
Position article and guidelines:
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology31 March 2023
Review:
Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells17 May 2022
Review:
Immuno-oncology trends: preclinical models, biomarkers, and clinical development12 January 2022
Altmetrics
What Our Editors Are Reading
In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC provides members with a 35% discount on Article Processing Charges (APCs) for all JITC articles submitted and accepted in 2023. This discount is applied post-acceptance, at which point a discount code is shared with the corresponding author.
For information on APC discounts and waivers – including those for members, editors or reviewers, low-income countries, or institutional arrangements – view the journal's APC policy.